The largest biotech event organised by a national bioindustry association (AseBio) in Europe and one of the biggest in the world will take place from 27 September to 1 October. To be held in Pamplona-Iruña, the capital of the region of Navarra, and a scientific cluster for biotechnology, BioSpain will feature
a combination of on-site networking opportunities and site visits, an online trade show, presentations,
and panels that will be accessible simultaneously on-site and online.
By applying the expertise, best practice, and emerging technologies of the logistics industry, biotech not only prevents the missteps that can destroy its products, it can also capitalise on opportunities to get to new markets faster, safer and more cost effectively.
The cannabis industry has established its first footholds in Europe over the past six years – but what comes next? European Biotechnology invited US-German American consultant, entrepreneur and author Marguerite Arnold to give a long-term future outlook.
So far, no gene and cell therapies have been approved to treat solid tumours. European Biotechnology spoke with Karen Miller, SVP Pipeline Research at Adaptimmune plc, about promising candidates, and the art of circumventing supply chain bottlenecks caused by the COVID-19 pandemic.
Isolating cells from whole blood or LRS cones carries the risk of red blood cell (RBC) contamination, which can have deleterious effects on downstream cell cultures.
The regulatory situation regarding the trade of medicinal cannabis currently varies enormously from country to country within the European Union. Unfortunately, there is still no full regulatory harmonization on a European level.
Effective bioprocess development starts with the targeted and time-saving generation of high-productivity strains already considering economic target values and regulatory requirements. The UNLOCK PICHIA technology platform comprises a large number of versatile expression tools for the generation and identification of effective industrial protein production strains without compromising development timelines.
The future of AAV vector-based therapies holds great promise if manufacturers can cope with the demand. While in-house manufacturing may be an option for some companies, partnering with a CDMO can be the best choice for others. Teaming up with a One-Stop-Shop CDMO can make it easier to achieve the project goals. There are many reasons for this.
The German Patent System has been a very patentee-friendly system, in particular for smaller patentees. Enforcement of patents has been relatively easy, affordable and fast.
Study start-up is a chaotic time. There are lots of moving parts. Lots of decisions to make and processes to establish. Lots of room for error. Mistakes can quickly derail a trial – and delays are endemic. That all represents a potential waste of time and resources – just at a moment when speed is of the essence. In many cases, the problem comes down to spreadsheets.